
Evolent Health (EVH) Stock Forecast & Price Target
Evolent Health (EVH) Analyst Ratings
Bulls say
Evolent Health Inc has demonstrated a robust growth trajectory, with expectations for a sequential EBITDA improvement of $10-15 million in the upcoming quarters, projecting $32.5 million for Q3 and $45 million for Q4. The company's strategic focus on enhancing its legacy Performance Suite MER by 500 basis points to 89% underscores its commitment to operational efficiency and margin enhancement, positioning it favorably for sustained growth. With strong top-line growth exceeding its mid-teens revenue target and significant business advancements in specialty-focused value-based care, Evolent Health is well-positioned for continued outperformance in the healthcare market.
Bears say
Evolent Health is experiencing significant revenue challenges, including an expected loss of approximately $100 million from its legacy Performance Suite, which may contribute to projected revenues of only about $850 million for that segment in 2026. The company's guidance for EBITDA in Q1 is a modest $20 million, with minimal growth anticipated for Q2, reflecting potential stagnation in performance. Furthermore, the reduction in earnings per share estimates for FY2026 and FY2027, coupled with a decreased price target, indicates a deteriorating financial outlook amidst ongoing market rationalization and client exits.
This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.
Evolent Health (EVH) Analyst Forecast & Price Prediction
Start investing in Evolent Health (EVH)
Order type
Buy in
Order amount
Est. shares
0 shares